EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.

Br J Cancer · 2017 · PMC5243999 · PMID 28006816

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

approaching significanceP =0.061so close (0.05 < p ≤ 0.1)

cfDNA+ patients more frequently had a higher ECOG performance status (LL3: P =0.0029; LL6: P =0.0022), greater tumour burden (measured as the sum of the longest diameter of target lesions; approaching significance in LL3: P =0.061; LL6: P =0.0001), more metastatic sites (LL3: P =0.0003; LL6: P <0.0001), and metastases to the bone (LL3 and LL6: P <0.0001) and liver (LL3: P <0.0001; LL6: P =0.0003; Table 2 ).

also in 2,640 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.